| akt-protein | |
|---|---|
| Symbol | AKT |
| Full Name | akt-protein |
| Type | Protein |
| UniProt | Search UniProt |
| Associated Diseases | AD, ADH, ALI, ALS, ALZHEIMER |
| KG Connections | 3999 edges |
Introduction
Akt (Protein Kinase B) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
AKT (Protein Kinase B, also known as PKB) is a serine/threonine kinase that serves as a central node in cell signaling, regulating cell survival, growth, proliferation, metabolism, and angiogenesis. Three AKT isoforms exist in humans: AKT1, AKT2, and AKT3, each with distinct but overlapping functions. AKT is frequently dysregulated in neurodegenerative diseases, making it an important therapeutic target (Manning & Cantley, 2007; Zhang et al., 2020). 1CitationOpen reference
--- 2CitationOpen reference
Gene and Protein Structure
AKT Gene Family
Three genes encode the AKT isoforms: 3CitationOpen reference
-
AKT1 (ENSG00000142208): Located on chromosome 14q32.33; ubiquitously expressed
-
AKT2 (ENSG00000105989): Located on chromosome 19q13.2; enriched in insulin-responsive tissues
-
AKT3 (ENSG00000147883): Located on chromosome 1q43; enriched in brain
Protein Domain Architecture
AKT (~480-505 amino acids depending on isoform) contains: 4CitationOpen reference
-
PH domain (Pleckstrin Homology, residues 1-100): Binds PIP3 at the plasma membrane
-
Turn motif (T308 in AKT1): Phosphorylation site for mTORC2
-
Hydrophobic motif (S473 in AKT1): Phosphorylation site for mTORC2
-
Kinase domain (residues 150-350): Catalytic serine/threonine kinase activity
-
Regulatory domain (C-terminal): Contains hydrophobic motif
Activation Mechanism
AKT activation follows PI3K activation: 5CitationOpen reference
-
Receptor tyrosine kinases activate PI3K
-
PI3K generates PIP3 at the plasma membrane
-
AKT’s PH domain binds PIP3, localizing AKT to the membrane
-
PDK1 phosphorylates AKT at T308 (activation loop)
-
mTORC2 phosphorylates AKT at S473 (hydrophobic motif)
-
Full activation requires both phosphorylation events
--- 6CitationOpen reference
Normal Biological Functions
Cell Survival and Anti-apoptosis
AKT promotes cell survival through multiple mechanisms: 7CitationOpen reference
-
Phosphorylates and inhibits BAD: Pro-apoptotic Bcl-2 family member (Datta et al., 1997)
-
Activates NF-κB: Transcription factor for survival genes
-
Inhibits caspases: Executioners of apoptosis
-
Phosphorylates MDM2: Promotes p53 degradation
Cell Growth and Proliferation
AKT regulates cell growth through: 8CitationOpen reference
-
mTORC1 activation: Promotes protein synthesis and cell growth
-
GSK3β inhibition: Stabilizes cyclin D1, promotes cell cycle progression
-
FOXO phosphorylation: Inhibits forkhead transcription factors (Brunet et al., 1999)
Metabolism
AKT is a key regulator of glucose and lipid metabolism: 9CitationOpen reference
-
Glucose uptake: Promotes GLUT4 translocation to membrane
-
Glycolysis: Increases glycolytic enzyme activity
-
Glycogen synthesis: Activates glycogen synthase via GSK3β inhibition
-
Lipid metabolism: Regulates SREBP and lipid synthesis (Yecies et al., 2011)
Neuronal Functions
In neurons, AKT signaling regulates: 10CitationOpen reference
-
Synaptic plasticity: Important for learning and memory (Horwood et al., 2006)
-
Neuronal development: Axon guidance, dendritic arborization
-
Neurotrophic factor signaling: BDNF, NGF signaling
-
Myelination: Oligodendrocyte survival and function
--- 2CitationOpen reference0
Role in Neurodegenerative Diseases
Alzheimer’s Disease
AKT dysregulation is central to AD pathogenesis: 2CitationOpen reference1
Insulin Signaling:
-
AD is increasingly viewed as type 3 diabetes with brain insulin resistance
-
AKT signaling is impaired in AD brain (Liu et al., 2011)
-
Restoring AKT signaling improves cognitive function in AD models
Tau Pathology:
-
GSK3β is a major tau kinase, inhibited by AKT
-
AKT deficiency leads to increased GSK3β activity and tau hyperphosphorylation
-
AKT activation reduces tau pathology in mouse models
Amyloid Metabolism:
-
AKT regulates amyloid precursor protein (APP) processing
-
PI3K/AKT signaling affects α-secretase activity
-
Modulating AKT influences Aβ production and clearance
Synaptic Dysfunction:
-
AKT is critical for synaptic plasticity and memory formation
-
AKT signaling is impaired at synapses in AD
-
BDNF/AKT signaling is compromised in AD brain
Parkinson’s Disease
AKT signaling is protective in PD:
Dopaminergic Neuron Survival:
-
AKT protects substantia nigra dopaminergic neurons
-
AKT activity is reduced in PD brain (Klein et al., 2006)
-
Alpha-synuclein inhibits AKT signaling
Mitochondrial Function:
-
AKT regulates mitochondrial dynamics and biogenesis
-
PGC-1α activation by AKT promotes mitochondrial health
-
AKT deficiency exacerbates mitochondrial dysfunction
Therapeutic Protection:
-
AKT overexpression protects against MPTP/6-OHDA toxicity
-
BDNF-mediated neuroprotection requires AKT signaling
Amyotrophic Lateral Sclerosis (ALS)
-
AKT signaling is dysregulated in ALS motor neurons (Koshy et al., 2010)
-
AKT activation protects against SOD1 mutant toxicity
-
AKT/GSK3β signaling modulates motor neuron survival
-
Crosstalk between AKT and TDP-43 pathology
Huntington’s Disease
-
Mutant huntingtin disrupts AKT signaling (Zainuddin et al., 2011)
-
AKT activity is reduced in HD models and patients
-
Restoring AKT improves mitochondrial function and reduces toxicity
-
AKT/mTOR signaling is impaired in HD
Therapeutic Targeting
AKT Activators
Therapeutic approaches to activate AKT signaling:
Small Molecule Activators:
-
SC79: Direct AKT activator, crosses BBB
-
PTEN inhibitors: Reduce PIP3 degradation
-
PDK1 activators
Neurotrophic Factors:
Receptor Agonists:
-
Insulin and insulin mimetics
-
IGF-1: Neuroprotective via AKT
Challenges
-
Systemic AKT activation may promote cancer
-
Isoform-specific targeting is important (AKT1 vs. AKT2 vs. AKT3)
-
Brain-penetrant molecules are required
-
Timing of intervention matters
Brain-Penetrant AKT Modulators
Recent drug development focuses on:
-
Selective AKT isoform inhibitors/activators
-
CNS-targeted compounds
-
Modulators of upstream/downstream signaling
Downstream Targets
Rather than direct AKT modulation, alternative approaches:
-
mTOR inhibitors/activators: Downstream of AKT
-
GSK3β modulators: Major AKT substrate
-
FOXO activators: Promote transcription of stress resistance genes
Pathway & Interaction Diagram
Interactive diagram showing AKT’s key relationships in the SciDEX knowledge graph (15 connections shown).
flowchart TD
AKT(["AKT"])
MTOR(["MTOR"])
TSC2(["TSC2"])
FOXO(["FOXO"])
mTOR(["mTOR"])
cell_growth("cell growth")
MTORC1(["MTORC1"])
AUTOPHAGY(["AUTOPHAGY"])
PTEN(["PTEN"])
LYC{"LYC"}
CTSG(["CTSG"])
MK2206{"MK2206"}
PI3K(["PI3K"])
BRSK2(["BRSK2"])
lycopene{"lycopene"}
AKT -->|"activates"| MTOR
AKT -->|"phosphorylates"| TSC2
AKT -.->|"inhibits"| TSC2
AKT -.->|"inhibits"| FOXO
AKT -->|"activates"| mTOR
AKT -->|"activates"| cell_growth
AKT -->|"activates"| MTORC1
AKT -.->|"inhibits"| AUTOPHAGY
PTEN -.->|"inhibits"| AKT
LYC -.->|"inhibits"| AKT
CTSG -.->|"inhibits"| AKT
MK2206 -.->|"inhibits"| AKT
PI3K -->|"activates"| AKT
BRSK2 -->|"activates"| AKT
lycopene -.->|"inhibits"| AKT
style AKT fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0See Also
External Links
External Links
Background
The study of Akt (Protein Kinase B) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.